Literature DB >> 3122217

RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes.

J W Janssen1, A C Steenvoorden, J Lyons, B Anger, J U Böhlke, J L Bos, H Seliger, C R Bartram.   

Abstract

We report on investigations aimed at detecting mutated RAS genes in a variety of preleukemic disorders and leukemias of myeloid origin. DNA transfection analyses (tumorigenicity assay) and hybridization to mutation-specific oligonucleotide probes established NRAS mutations in codon 12 or 61 of 4/9 acute myelocytic leukemias (AML) and three AML lines. Leukemic cells of another AML patient showed HRAS gene activation. By using a rapid and sensitive dot-blot screening procedure based on the combination of in vitro amplification of RAS-specific sequences and oligonucleotide hybridization we additionally screened 15 myelodysplastic syndromes, 26 Philadelphia chromosome-positive chronic myelocytic leukemias in chronic or acute phase, and 19 other chronic myeloproliferative disorders. A mutation within NRAS codon 12 could thus be demonstrated in a patient with idiopathic myelofibrosis and in another with chronic myelomonocytic leukemia. Moreover, mutated NRAS sequences were detected in lymphocytes, in granulocytes, as well as in monocytes/macrophages of the latter case.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3122217      PMCID: PMC299726          DOI: 10.1073/pnas.84.24.9228

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  41 in total

1.  Acute myelogenous leukemia: a human cell line responsive to colony-stimulating activity.

Authors:  H P Koeffler; D W Golde
Journal:  Science       Date:  1978-06-09       Impact factor: 47.728

2.  Isolation and preliminary characterization of a human transforming gene from T24 bladder carcinoma cells.

Authors:  M Goldfarb; K Shimizu; M Perucho; M Wigler
Journal:  Nature       Date:  1982-04-01       Impact factor: 49.962

3.  Demonstration of granulocyte, monocyte, and endothelial cell antigens by double fluorochromatic microcytotoxicity testing.

Authors:  J S Thompson; V Overlin; C D Severson; T J Parsons; J Herbick; R G Strauss; C P Burns; F H Claas
Journal:  Transplant Proc       Date:  1980-09       Impact factor: 1.066

Review 4.  Cytogenetics of preleukemia.

Authors:  P C Nowell
Journal:  Cancer Genet Cytogenet       Date:  1982-03

5.  Proposals for the classification of the myelodysplastic syndromes.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Br J Haematol       Date:  1982-06       Impact factor: 6.998

6.  Molecular cloning and the total nucleotide sequence of the human c-Ha-ras-1 gene activated in a melanoma from a Japanese patient.

Authors:  T Sekiya; M Fushimi; H Hori; S Hirohashi; S Nishimura; T Sugimura
Journal:  Proc Natl Acad Sci U S A       Date:  1984-08       Impact factor: 11.205

7.  Characterization of a human colon/lung carcinoma oncogene.

Authors:  M S McCoy; J J Toole; J M Cunningham; E H Chang; D R Lowy; R A Weinberg
Journal:  Nature       Date:  1983-03-03       Impact factor: 49.962

8.  Establishment and characterization of a human acute monocytic leukemia cell line (THP-1).

Authors:  S Tsuchiya; M Yamabe; Y Yamaguchi; Y Kobayashi; T Konno; K Tada
Journal:  Int J Cancer       Date:  1980-08       Impact factor: 7.396

9.  Comparative biochemical properties of normal and activated human ras p21 protein.

Authors:  J P McGrath; D J Capon; D V Goeddel; A D Levinson
Journal:  Nature       Date:  1984 Aug 23-29       Impact factor: 49.962

10.  Cell lines derived from a human myelomonocytic leukaemia.

Authors:  T R Bradley; G Pilkington; M Garson; G S Hodgson; N Kraft
Journal:  Br J Haematol       Date:  1982-08       Impact factor: 6.998

View more
  36 in total

Review 1.  Promising approaches in acute leukemia.

Authors:  J Cortes; H M Kantarjian
Journal:  Invest New Drugs       Date:  2000-02       Impact factor: 3.850

Review 2.  Molecular biology in medicine.

Authors:  B D Young
Journal:  Postgrad Med J       Date:  1992-04       Impact factor: 2.401

Review 3.  RAS inhibitors in hematologic cancers: biologic considerations and clinical applications.

Authors:  D M Beaupre; R Kurzrock
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

4.  The differential palmitoylation states of N-Ras and H-Ras determine their distinct Golgi subcompartment localizations.

Authors:  Stephen J Lynch; Harriet Snitkin; Iwona Gumper; Mark R Philips; David Sabatini; Angel Pellicer
Journal:  J Cell Physiol       Date:  2015-03       Impact factor: 6.384

Review 5.  Pathogenesis of idiopathic myelofibrosis: role of growth factors.

Authors:  J T Reilly
Journal:  J Clin Pathol       Date:  1992-06       Impact factor: 3.411

6.  Transforming genes and chromosome aberrations in therapy-related leukemia and myelodysplastic syndrome.

Authors:  K Inokuchi; N Amuro; M Futaki; K Dan; T Shinohara; S Kuriya; T Okazaki; T Nomura
Journal:  Ann Hematol       Date:  1991-06       Impact factor: 3.673

7.  Oncogenicity of human N-ras oncogene and proto-oncogene introduced into retroviral vectors.

Authors:  M Souyri; I Vigon; M Charon; P Tambourin
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

8.  Detection of Borrelia burgdorferi using the polymerase chain reaction.

Authors:  D C Malloy; R K Nauman; H Paxton
Journal:  J Clin Microbiol       Date:  1990-06       Impact factor: 5.948

Review 9.  The balance of protein farnesylation and geranylgeranylation during the progression of nonalcoholic fatty liver disease.

Authors:  Yue Zhao; Tian-Yu Wu; Meng-Fei Zhao; Chao-Jun Li
Journal:  J Biol Chem       Date:  2020-03-05       Impact factor: 5.157

10.  High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients.

Authors:  Jeffrey W Tyner; Heidi Erickson; Michael W N Deininger; Stephanie G Willis; Christopher A Eide; Ross L Levine; Michael C Heinrich; Norbert Gattermann; D Gary Gilliland; Brian J Druker; Marc M Loriaux
Journal:  Blood       Date:  2008-12-15       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.